Savara Inc. Announces Publication of Phase 3 IMPALA-2 Trial Results in NEJM, Highlighting Efficacy of Molgramostim for Autoimmune PAP
Reuters
Aug 21
<a href="https://laohu8.com/S/SVRA">Savara Inc</a>. Announces Publication of Phase 3 IMPALA-2 Trial Results in NEJM, Highlighting Efficacy of Molgramostim for Autoimmune PAP
Savara Inc. has announced that the results from its Phase 3 IMPALA-2 clinical trial will be published online in the New England Journal of Medicine (NEJM) on August 21, 2025. The trial focused on the use of inhaled molgramostim therapy in patients with autoimmune Pulmonary Alveolar Proteinosis (PAP), a rare respiratory disease. The study, characterized as the largest and longest Phase 3 clinical trial conducted in autoimmune PAP, demonstrated that 48 weeks of daily administration of molgramostim reduced pulmonary surfactant burden and improved pulmonary gas transfer, respiratory health-related quality of life, and patient functionality. The treatment was well tolerated with no notable safety concerns. The manuscript detailing the trial results will be available on the company's website following its publication in NEJM.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820194710) on August 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.